| FAQ/Help |
| Calendar |
| Search |
| Today's Posts |
09-01-2016, 02:50 PM
|
#1 | ||
|
|||
|
News Gatherer
Community Support Team
|
FierceBiotech Sunovion pays $624M for Canada's Cynapsus, lead PhIII Parkinson's med FierceBiotech Sunovion Pharmaceuticals is to pay a 120% premium to buy out Canadian biotech Cynapsus Therapeutics as it looks to get its hands on the company's late-stage Parkinson's disease candidate. Cynapsus ($CYNA) closed before the deal was announced at ... Toronto pharmaceutical company behind new Parkinson's drug bought for $820 millionFinancial Post Sunovion Swallows Up Cynapsus in $624 Million DealPharmaLive (press release) (subscription) Sunovion to buy Cynapsus for $620 millionThe Boston Globe InvestorGuide -MarketWatch -Market Exclusive all 57 news articles » More... |
||
|
 Reply With Quote
|
| Reply |
|
|
Similar Threads
|
||||
| Thread | Forum | |||
| Novartis cancer drug to be tested for Parkinson's Disease - FierceBiotech | Parkinson's News | |||
| Brain surgery for Parkinson's pays off in quality of life - The Missoulian | Parkinson's News | |||
| inhaled l-dopa Civitas nails $55M venture round for a PhIII Parkinson's study | Parkinson's Disease | |||
| Cynapsus' sublingual strip for severe Parkinson's reduces side effects in study | Parkinson's Disease | |||
Sunovion pays $624M for Canada's Cynapsus, lead PhIII Parkinson's med - FierceBiotech
Linear Mode
